A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Hereditary Angioedema

Interventions

DRUG

BCX4161

Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose

Trial Locations (1)

Quotient Clinical Ltd, Ruddington